[1]STEVENS L A, DJURDJEV O, CARDEW S, et al.Calcium,phosphate,and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes[J].Journal of the American Society of Nephrology, 2004, 15(3):770-779
[2]GOODMAN W G, GOLDIN J, KUIZON B D, et al.Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis[J].N Engl J Med, 2000, 342(20):1478-1483
[3]MILLINER D S, ZINSMEISTER A R, LIEBERMAN E, et al.Soft tissue calcification in pediatric patients with end-stage renal disease[J].Kidney Int, 1990, 38(5):931-936
[4]WANNER C, AMANN K, SHOJI T.The heart and vascular system in dialysis[J].Lancet, 2016, 388(10041):276-284
[5]GRANJA C A, JUERGENSEN P, FINKELSTEIN F O.Phosphate balance in peritoneal dialysis patients: role of ultrafiltration [J].[J].Contributions to nephrology, 2009, 163:198-205
[6]MCCARTHY J T, WILLIAMS A W, JOHNSON W J.Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function[J].The Journal of laboratory and clinical medicine, 1994, 123(4):495-505
[7]PAGé D E, KNOLL G A, CHEUNG V.The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients [J].[J].Advances in peritoneal dialysis Conference on Peritoneal Dialysis, 2002, 18:189-191
[8]Botelho C, Rodrigues A, Oliveira J C, et al.Peritoneal phosphate removal varies by peritoneal dialysis regimen: an underestimated parameter of phosphate control[J].Journal of Nephrology, 2013, 26(1):183-190
[9]BRENER Z Z, KOTANKO P, THIJSSEN S, et al.Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians[J].The American journal of the medical sciences, 2010, 339(5):453-456
[10]ROCCO M, SOUCIE J M, PASTAN S, et al.Peritoneal dialysis adequacy and risk of death[J].Kidney international, 2000, 58(1):446-457
[11]MOIST L M, PORT F K, ORZOL S M, et al.Predictors of loss of residual renal function among new dialysis patients[J].J Am Soc Nephrol, 2000, 11(3):556-564
[12]WANG A Y, LAI K N.The importance of residual renal function in dialysis patients[J].Kidney international, 2006, 69(10):1726-1732
[13]MEDCALF J F, HARRIS K P, WALLS J.Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis[J].Kidney Int, 2001, 59(3):1128-1133
[14]LI P K, CHOW K M, WONG T Y, et al.Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysisA randomized,controlled study[J].Annals of internal medicine, 2003, 139(2):105-112
[15]SUZUKI H, KANNO Y, SUGAHARA S, et al.Effects of an angiotensin II receptor blocker,valsartan,on residual renal function in patients on CAPD[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, 43(6):1056-1064
[16]SHEN J I, SAXENA A B, VANGALA S, et al.Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study [J].[J].Bmc Nephrology, 2017, 18:-
[17]RODRIGUEZ-CARMONA A, PEREZ-FONTAN M, GARCA-NAVEIRO R, et al.Compared time profiles of ultrafiltration,sodium removal,and renal function in incident CAPD and automated peritoneal dialysis patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, 44(1):132-145
[18]GRINFELD J, INABA A, HUTCHISON A J.Update and critical appraisal of sevelamer in the management of chronic renal failure [J].[J].Open access journal of urology, 2010, 2:161-170
[19]SALUSKY I B.A new era in phosphate binder therapy: What are the options? [J]. [J].Kidney International, 2006, 70(105):S10-S15
[20]DE FREITAS D, DONNE R L, HUTCHISON A J.Lanthanum carbonate--a first line phosphate binder?[J].Semin Dial, 2007, 20(4):325-328
[21]SMITH E R.The use of fibroblast growth factor 23 testing in patients with kidney disease[J].Clin J Am Soc Nephrol, 2014, 9(7):1283-1303
[22]HABBOUS S, PRZECH S, ACEDILLO R, et al.The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis[J].Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 32(1):111-125
[23]FLOEGE J.Phosphate binders in chronic kidney disease: a systematic review of recent data[J].Journal of nephrology, 2016, 29(3):329-340
[24]TIEU C, MOREIRA R K, SONG L M W K, et al.A case report of sevelamer-associated recto-sigmoid ulcers [J].[J].BMC Gastroenterol, 2016, 16:-
[25]BANSAL V, AGGARWAL P, MITTAL A, et al.Colonic Mass Secondary to Sevelamer-Associated Mucosal Injury [J].[J].Acg Case Reports Journal, 2017, 4(1):-
[26]TERMORSHUIZEN F, KOREVAAR J C, DEKKER F W, et al.The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, 41(6):1293-1302
[27]BERNARDO A P, CONTESSE S A, BAJO M A, et al.Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis[J].Clin J Am Soc Nephrol, 2011, 6(3):591-597
[28]Pribil A B, Hofer T S, Randolf B R, et al.Structure and dynamics of phosphate ion in aqueous solution: An ab initio QMCF MD study[J].Journal of Computational Chemistry, 2008, 29(14):2330-2334
[29]ASANO M, ISHII T, HIRAYAMA A, et al.Differences in peritoneal solute transport rates in peritoneal dialysis[J].Clin Exp Nephrol, 2019, 23(1):122-134
[30]Bammens B, Evenepoel P, Verbeke K, et al.Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms[J].Kidney Int, 2003, 64(6):2238-2243
[31]WANG A Y, WANG M, WOO J, et al.A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients[J].Kidney Int, 2002, 62(2):639-647
[32]SEDLACEK M, DIMAANO F, URIBARRI J.Relationship between phosphorus and creatinine clearance in peritoneal dialysis: clinical implications[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2000, 36(5):1020-1024
[33]BADVE S V, ZIRNMERMAN D L, KNOLL G A, et al.Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality,Independent of Peritoneal Transport Characteristics[J].Clinical Journal of the American Society of Nephrology, 2008, 3(6):1711-1717
[34]Courivaud C, Davenport A.PHOSPHATE REMOVAL BY PERITONEAL DIALYSIS: THE EFFECT OF TRANSPORTER STATUS AND PERITONEAL DIALYSIS PRESCRIPTION[J].Peritoneal Dialysis International, 2016, 36(1):85-93
[35]BAMMENS B, EVENEPOEL P, VERBEKE K, et al.Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, 46(3):512-519
[36]JUERGENSEN P, ERAS J, MCCLURE B, et al.The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients[J].International Journal of Artificial Organs, 2005, 28(12):1219-1223
[37]Schmitt C P, Borzych D, Nau B, et al.DIALYTIC PHOSPHATE REMOVAL: A MODIFIABLE MEASURE OF DIALYSIS EFFICACY IN AUTOMATED PERITONEAL DIALYSIS[J].Peritoneal Dialysis International, 2009, 29(4):465-471
